Caplin Point Laboratories Ltd.

BSE: CAPLIPOINT524742ISIN INE475E01026

Healthcare
Pharmaceuticals
BSE 500

Share price

₹2,416.10+54.10 (+2.29%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹2,990.60
52W low: ₹1,502.45
Off 52W high: -19.21%
1M return: -7.20%
3M return: -5.00%
6M return: +31.35%
1Y return: +20.85%
20D avg volume: 7,809
50 DMA: ₹2,557.84
200 DMA: ₹2,170.49

Key ratios Consolidated

Market cap: ₹18,365 Cr
Current price: ₹2,416.10
52W high / low: ₹2,990.60 / ₹1,502.45
Face value: ₹2.00
P/E: 27.08
P/B: 5.12
EPS (TTM): ₹89.20
Book value / share: ₹471.90
ROE: —
ROCE: 22.00%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-93.61 Cr
Interest cover: 923.75
Dividend yield: 0.33%
Dividend / share (TTM): ₹8.00
Payout: 8.97%
Cash conversion cycle: 160.0 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	610.36	600.16	542.77	534.04	510.22	502.45	492.96	483.10	458.96	453.22	435.50	410.06
	33.55	28.36	33.68	30.37	23.14	25.74	31.36	20.77	18.56	17.29	17.18	20.43
	643.91	628.52	576.45	564.41	533.36	528.19	524.32	503.87	477.52	470.51	452.68	430.49
	418.68	415.08	372.54	363.43	348.93	351.60	347.05	335.31	323.16	324.54	307.30	284.60
	107.06	102.11	89.24	92.34	73.51	60.84	59.80	69.23	63.65	57.87	50.95	66.85
	196.36	209.02	128.00	121.68	113.50	138.77	139.43	122.33	74.48	121.78	179.77	129.33
	54.13	52.62	49.78	47.23	43.16	46.51	46.77	44.29	40.15	36.77	36.67	35.08
	0.18	0.36	0.18	0.16	0.18	0.17	0.18	0.21	0.05	0.15	0.17	0.18
	21.62	18.80	19.28	18.40	16.29	17.04	16.20	16.76	15.96	16.40	13.90	11.77
	97.55	98.30	88.16	87.34	94.06	86.68	88.55	85.23	81.52	79.85	66.44	73.48
	225.23	213.44	203.91	200.98	184.43	176.59	177.27	168.56	154.36	145.97	145.38	145.89
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.00	0.00
	225.23	213.44	203.91	200.98	184.43	176.59	177.27	168.56	154.36	146.03	145.38	145.89
	46.13	40.56	38.03	40.77	33.70	31.39	37.19	37.65	29.46	24.80	25.58	29.86
	179.09	172.88	165.86	160.23	150.76	145.28	140.07	130.81	124.92	121.23	119.83	116.14
	23.27	22.38	21.56	20.32	20.10	18.75	18.28	17.22	16.32	16.01	15.44	15.13
Key metrics
	247.03	232.60	223.37	219.54	200.90	193.80	193.65	185.53	170.37	162.58	159.45	157.84
	40.50%	38.80%	41.20%	41.10%	39.40%	38.60%	39.30%	38.40%	37.10%	35.90%	36.60%	38.50%
	29.30%	28.80%	30.60%	30.00%	29.50%	28.90%	28.40%	27.10%	27.20%	26.70%	27.50%	28.30%
	—	5.80%	—	6.20%	—	6.10%	—	—	—	—	—	—
	19.60%	19.40%	10.10%	10.50%	11.20%	10.90%	13.20%	17.80%	—	—	—	—
	18.80%	19.00%	18.40%	22.50%	20.70%	19.80%	16.90%	12.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	2,287	2,187	1,937	1,694	1,467	1,269	1,061	863.20	648.69	539.84	405.10
	125.96	115.54	96.43	66.94	55.98	38.75	23.54	41.33	19.03	12.66	6.39
	2,413	2,303	2,034	1,761	1,523	1,308	1,085	904.53	667.72	552.51	411.48
	1,570	1,500	1,357	1,197	1,071	922.34	771.21	635.07	440.84	364.13	289.70
	390.75	357.20	248.45	239.81	223.04	192.31	129.82	108.12	95.12	90.22	64.78
	655.06	572.20	575.70	558.92	519.03	397.13	259.57	500.14	203.73	150.35	—
	203.76	199.15	177.72	143.59	136.99	115.30	102.53	67.76	47.11	39.14	—
	0.88	0.87	0.61	0.78	0.78	0.70	1.59	0.32	0.06	0.06	0.13
	78.10	72.77	65.96	53.44	44.99	46.90	36.97	31.62	23.43	—	—
	371.35	361.51	341.98	274.89	225.47	201.93	158.38	122.21	81.47	67.75	—
	843.56	802.75	676.79	564.16	451.27	385.82	313.62	269.46	226.88	188.38	121.78
	0.00	0.04	0.00	0.27	0.08	0.00	0.00	0.00	0.00	0.00	0.00
	843.56	802.79	676.79	564.43	451.35	385.82	313.62	269.46	226.88	188.38	121.78
	165.49	153.06	135.69	103.01	74.36	77.37	62.18	54.38	50.32	43.74	25.73
	678.06	649.73	541.09	461.42	376.99	308.45	251.44	215.08	176.56	144.63	96.05
	87.53	84.36	70.57	60.19	49.62	39.61	32.03	28.42	23.35	—	—
Key metrics
	922.54	876.43	743.36	618.65	497.12	433.42	352.18	301.40	250.37	188.44	121.91
	40.33%	40.10%	38.40%	36.50%	33.90%	34.10%	33.20%	34.90%	38.60%	34.90%	30.10%
	29.64%	29.70%	27.90%	27.20%	25.70%	24.30%	23.70%	24.90%	27.20%	26.80%	23.70%
	—	22.00%	23.30%	—	—	—	—	—	—	—	—
	15.01%	12.90%	14.40%	15.50%	15.50%	19.60%	22.90%	33.10%	20.20%	33.30%	—
	19.60%	20.10%	17.30%	22.40%	22.20%	22.70%	16.90%	21.80%	22.10%	50.60%	—
	—	275.10	240.85	—	—	—	—	—	—	—	—
	—	0.81	0.80	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	-93.61	-198.90	—	—	—	—	—	—	—	—
	—	160.0	141.5	—	—	—	—	—	—	—	—
Balance sheet
	—	4,045	3,209	—	—	—	—	—	—	—	—
	—	2,586	2,134	—	—	—	—	—	—	—	—
	—	94.18	199.45	—	—	—	—	—	—	—	—
	—	825.81	632.49	—	—	—	—	—	—	—	—
	—	428.86	336.10	—	—	—	—	—	—	—	—
	—	250.07	205.25	—	—	—	—	—	—	—	—
	—	547.49	530.32	—	—	—	—	—	—	—	—
	—	296.03	217.58	—	—	—	—	—	—	—	—
	—	385.94	306.38	—	—	—	—	—	—	—	—
	—	0.57	0.55	—	—	—	—	—	—	—	—
	—	0.57	0.55	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	3,631	2,886	—	—	—	—	—	—	—	—
Cash flow
	—	523.23	432.37	—	—	—	—	—	—	—	—
	—	-582.29	-334.73	—	—	—	—	—	—	—	—
	—	-46.46	-38.32	—	—	—	—	—	—	—	—
	—	248.13	191.52	—	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	202.95	191.36	189.22	175.18	182.57	173.61	185.23	207.93	185.64	139.38	132.83	179.22
	62.79	61.08	31.73	59.22	32.03	41.25	28.83	43.01	21.50	36.18	17.90	24.49
	265.74	252.44	220.95	234.40	214.60	214.86	214.06	250.94	207.14	175.56	150.73	203.71
	115.15	114.72	103.94	105.40	102.14	104.70	113.89	116.28	110.46	88.65	76.29	96.51
	42.12	45.80	39.47	34.92	38.62	34.25	33.29	32.72	36.38	40.18	43.43	45.84
	27.42	24.67	23.45	21.21	13.18	17.39	19.24	24.36	16.18	22.91	13.04	19.97
	13.73	13.15	13.41	11.54	9.63	14.39	13.89	12.99	10.86	9.77	9.52	9.10
	0.05	0.05	0.07	0.05	0.04	0.04	0.04	0.02	0.02	0.02	0.03	0.02
	6.56	6.90	6.37	6.02	6.14	6.09	6.01	6.49	6.18	6.93	6.76	6.72
	36.65	39.04	26.97	29.61	28.26	28.88	33.23	35.00	33.03	28.43	18.44	24.23
	150.59	137.72	117.01	129.00	112.46	110.16	100.17	134.66	96.68	86.91	74.43	107.19
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	150.59	137.72	117.01	129.00	112.46	110.16	100.17	134.66	96.68	86.91	74.43	107.19
	30.21	28.22	29.73	26.41	26.57	23.66	25.46	28.92	24.14	17.03	18.98	25.10
	120.38	109.50	87.28	102.59	85.89	86.50	74.71	105.74	72.54	69.88	55.45	82.09
	15.84	15.89	11.49	13.50	11.30	11.37	9.83	13.92	9.55	9.20	7.30	10.82
Key metrics
	157.20	144.67	123.45	135.07	118.64	116.29	106.22	141.17	102.88	93.86	81.22	113.93
	77.50%	75.60%	65.20%	77.10%	65.00%	67.00%	57.30%	67.90%	55.40%	67.30%	61.10%	63.60%
	59.30%	57.20%	46.10%	58.60%	47.00%	49.80%	40.30%	50.90%	39.10%	50.10%	41.70%	45.80%
	—	6.70%	—	7.00%	—	6.40%	—	—	—	—	—	—
	11.20%	10.20%	2.20%	-15.80%	-1.70%	24.60%	39.40%	16.00%	—	—	—	—
	40.20%	26.60%	16.80%	-3.00%	18.40%	23.80%	34.70%	28.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	758.71	738.33	752.41	625.09	528.61	528.06	482.68	527.83	536.91	426.57	347.72
	214.82	195.37	134.59	105.84	99.00	56.55	18.62	65.97	35.40	23.31	6.22
	973.53	933.70	887.00	730.93	627.61	584.61	501.30	593.80	572.31	449.89	353.94
	439.21	426.18	445.33	365.19	334.46	334.30	291.36	340.67	369.65	303.83	260.53
	162.31	158.82	136.64	172.13	151.35	156.01	112.48	95.73	94.04	90.22	64.47
	96.75	82.51	77.17	76.77	48.38	57.64	82.92	143.18	145.50	92.28	97.34
	51.83	47.72	52.13	38.11	36.68	30.47	26.59	25.00	42.01	38.82	29.65
	0.22	0.20	0.12	0.10	0.12	0.09	0.17	0.18	0.06	0.06	0.13
	25.85	25.43	24.77	27.08	25.65	25.77	22.44	19.65	20.84	18.99	13.26
	132.27	123.87	130.14	94.68	—	73.32	47.33	57.66	69.70	65.85	—
	534.32	507.52	441.67	365.74	293.15	250.31	209.94	253.12	202.65	146.05	93.41
	0.00	0.00	0.00	—	—	—	—	—	—	—	—
	534.32	507.52	441.67	365.74	293.15	250.31	209.94	253.12	202.65	146.05	93.41
	114.57	110.94	102.18	82.03	58.89	62.44	53.71	55.49	54.49	43.74	22.55
	419.75	396.58	339.49	283.71	234.26	187.87	156.23	197.64	148.17	102.31	70.86
	56.72	52.17	44.67	37.36	30.89	24.82	20.65	26.13	19.60	—	—
Key metrics
	560.39	533.15	466.56	392.92	318.92	276.17	232.55	272.95	223.55	165.10	106.80
	73.86%	72.20%	62.00%	62.90%	60.30%	52.30%	48.20%	51.70%	41.60%	38.70%	30.70%
	55.32%	53.70%	45.10%	45.40%	44.30%	35.60%	32.40%	37.40%	27.60%	24.00%	20.40%
	—	24.60%	25.80%	—	—	—	—	—	—	—	—
	1.25%	-1.90%	20.40%	18.30%	0.10%	9.40%	-8.60%	-1.70%	25.90%	22.70%	—
	18.96%	16.80%	19.70%	21.10%	24.70%	20.30%	-21.00%	33.40%	44.80%	44.40%	—
	—	170.15	139.31	—	—	—	—	—	—	—	—
	—	0.54	0.58	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	-44.09	-99.64	—	—	—	—	—	—	—	—
	—	127.8	87.6	—	—	—	—	—	—	—	—
Balance sheet
	—	2,212	1,814	—	—	—	—	—	—	—	—
	—	975.88	825.69	—	—	—	—	—	—	—	—
	—	44.09	99.64	—	—	—	—	—	—	—	—
	—	265.96	175.33	—	—	—	—	—	—	—	—
	—	85.66	66.26	—	—	—	—	—	—	—	—
	—	36.25	32.14	—	—	—	—	—	—	—	—
	—	219.68	201.59	—	—	—	—	—	—	—	—
	—	93.02	60.96	—	—	—	—	—	—	—	—
	—	144.17	99.85	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	2,050	1,701	—	—	—	—	—	—	—	—
Cash flow
	—	214.78	195.87	—	—	—	—	—	—	—	—
	—	-224.77	-140.20	—	—	—	—	—	—	—	—
	—	-45.81	-38.10	—	—	—	—	—	—	—	—
	—	44.63	56.56	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +11.78%
Sales CAGR 5Y: +8.87%
Profit CAGR 3Y: +19.18%
Profit CAGR 5Y: +20.48%
Sales YoY (TTM): +1.25%
Profit YoY (TTM): +18.96%

Consolidated

Sales CAGR 3Y: +14.25%
Sales CAGR 5Y: +15.56%
Profit CAGR 3Y: +19.89%
Profit CAGR 5Y: +20.91%
Sales YoY (TTM): +15.01%
Profit YoY (TTM): +19.60%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 70.59%

Quarter	September 2026	June 2026
Promoter %	70.59%	70.59%

Holder	Type	Holding	Previous	Change
P VIJAYALAKSHMI	Promoter Group	24.71%	24.71%	0.00%
PAARTHIPAN C C	Promoter	18.64%	18.64%	0.00%
ASHOK GORKEY PARTHEEBAN	Promoter Group	11.91%	11.91%	0.00%
PARTHEEBAN VIVEK SIDDARTH	Promoter Group	11.85%	11.85%	0.00%
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS	Public	2.81%	2.87%	-0.06%
MAY INDIA PROPERTY PRIVATE LIMITED	Promoter Group	2.79%	2.79%	0.00%
UTI NIFTY 500 INDEX FUND	Public	1.38%	—	—
FIRST DIMENSION HOLDINGS PRIVATE LIMITED	Promoter Group	0.49%	0.49%	0.00%
KIRAVIZ PROPERTIES AND CONSULTANCY LLP	Promoter Group	0.20%	0.20%	0.00%
VISALATCHI P	Promoter Group	0.00%	0.00%	0.00%
KOTTESWARI B	Promoter Group	0.00%	0.00%	0.00%
CHELLAPPAN POOVALAMBEDU KANDASAMY	Promoter Group	0.00%	0.00%	0.00%
SOUNDARI B	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Caplin Point Laboratories Ltd.	18,365	2,416.10	27.08	22.00%	+15.01% TTM	+19.60% TTM	+20.85%

Filings & corporate actions

Recent announcements

Analyst / investor Call for the quarter and half ended September 30, 20262 Nov 2026 · Company Update / Analyst / Investor Meet
Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve the unaudited financial ....2 Nov 2026 · Board Meeting / Board Meeting
Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter and half year ended September 30, 2026.7 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window for the quarter and half year ended September 30, 2026 commencing from October 01, 2026.28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Voting Results and Scrutinizer Report for the 35th Annual General Meeting25 Sep 2026 · AGM/EGM / AGM
Proceedings of 35th Annual General Meeting of the Company25 Sep 2026 · AGM/EGM / AGM
Clarification with respect to Volume Movement25 Sep 2026 · Company Update / General
The Exchange has sought clarification from Caplin Point Laboratories Ltd on September 25, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.25 Sep 2026 · Company Update / Clarification
Newspaper Publication for Notice of 35th AGM and E-Voting Information4 Sep 2026 · Company Update / Newspaper Publication
Letter to Shareholders regarding dispatch of 35th AGM Notice and Annual Report for the Financial year 2025-264 Sep 2026 · Company Update / General
Business Responsibility and Sustainability Report for the Financial Year 2025-263 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Notice of the 35th Annual General Meeting of the Company3 Sep 2026 · AGM/EGM / AGM
Annual Report for the Financial Year 2025-263 Sep 2026 · Others / Reg. 34 (1) Annual Report
Newspaper Publication for convening 35th AGM of the Company through Video Conferencing.2 Sep 2026 · Company Update / Newspaper Publication
Receipt of Good Manufacturing Practices (GMP) Compliance Certificate by Caplin One Labs Limited (COL), a subsidiary Company, from INVIMA1 Sep 2026 · Company Update / General
Completion of Unannounced USFDA Inspection at the facility of Caplin Steriles Limited (Company''s subsidiary)21 Aug 2026 · Company Update / General
Transcript for Earnings call- Q1- FY 2026-2719 Aug 2026 · Company Update / Earnings Call Transcript
Audio Recording of Earnings call for the Quarter ended June 30, 202612 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Presentation for the Earnings Call for the Quarter ended June 30, 2026.12 Aug 2026 · Company Update / Investor Presentation
The Board of Director in its meeting held today, August 12, 2026, approved the appointment of directors.12 Aug 2026 · Company Update / Change in Management
Financial Results for the quarter ended June 30, 202612 Aug 2026 · Result / Financial Results
Record date for Final Dividend is September 18, 202612 Aug 2026 · Corp. Action / Dividend
Board meeting outcome for meeting held on August 12, 202612 Aug 2026 · Board Meeting / Outcome of Board Meeting
Post-results conference call invite for the quarter ended June 30, 2026 is enclosed herewith.30 Jul 2026 · Company Update / Analyst / Investor Meet
Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1. Unaudited financial ....29 Jul 2026 · Board Meeting / Board Meeting
Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended June 30, 202611 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of closure of Trading Window commencing from July 01, 202627 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper advertisement for transfer of Unclaimed dividend and shares to IEPF22 Jun 2026 · Company Update / Newspaper Publication
Annual Secretarial Compliance report for the year ended March 31, 202629 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201522 May 2026 · Company Update / Analyst / Investor Meet
Transcript for Earnings call- Q4- FY 2025-2621 May 2026 · Company Update / Earnings Call Transcript
Earnings call for Q4(2025-26)14 May 2026 · Company Update / Analyst / Investor Meet
Press release regarding receipt of final approval by our subsidiary, Caplin Steriles Limited, from USFDA, for Foscarnet Sodium Injection14 May 2026 · Company Update / Press Release / Media Release
The Board at its meeting held today, May 14, 2026, had declared Interim Dividend of INR.4.00 (200%) per equity share for the FY 2025-26 and fixed the Record date as May 30, 2026.14 May 2026 · Corp. Action / Dividend
Financial Results for the Quarter and Year ended March 31, 202614 May 2026 · Result / Financial Results
The Board at its meeting held today, May 14, 2026, had 1. Approved the Audited standalone and consolidated financial results of the Company for the year ended March 31, 2026, along with ....14 May 2026 · Board Meeting / Outcome of Board Meeting
Q4 post-results conference call invite is enclosed herewith.7 May 2026 · Company Update / Analyst / Investor Meet
Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Audited financial ....7 May 2026 · Board Meeting / Board Meeting
Press release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from USFDA for Calcium Gluconate Injection USP5 May 2026 · Company Update / Press Release / Media Release
Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 20266 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 4.0000	18 Sep 2026	18 Sep 2026	—
Interim Dividend - Rs. - 4.0000	29 May 2026	30 May 2026	—
Final Dividend - Rs. - 3.0000	12 Sep 2025	12 Sep 2025	—
Interim Dividend - Rs. - 3.0000	30 May 2025	30 May 2025	—
Final Dividend - Rs. - 2.5000	23 Sep 2024	—	—

Board meetings

12 Nov 2026 Board Meeting - Financial Results
12 Aug 2026 Board Meeting - Financial Results